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Maho Nagasawa1,2, Balthasar A. Heesters1,2, Chantal M.A. Kradolfer1,2, Lisette Krabbendam1,2, Itziar Martinez-Gonzalez1,2, Marjolein J.W. de Bruijn3,
Korneliusz Golebski1,2, Rudi W. Hendriks3, Ralph Stadhouders3,4, Hergen Spits1,2, and Suzanne M. Bal1,2,3
Recently, human ILCs that express CD117 and CD127 but lack CRTH2 and NKp44 have been shown to contain precursors of
ILC1, ILC2, and ILC3. However, these ILCs have not been extensively characterized. We performed an unbiased hierarchical
stochastic neighbor embedding (HSNE) analysis of the phenotype of peripheral blood CD117+ ILCs, which revealed the
presence of three major subsets: the first expressed NKp46, the second expressed both NKp46 and CD56, and the third
expressed KLRG1, but not NKp46 or CD56. Analysis of their cytokine production profiles and transcriptome revealed that
NKp46+ ILCs predominantly develop into ILC3s; some of them can differentiate into ILC1/NK-like cells, but they are unable to
develop into ILC2s. In contrast, KLRG1+ ILCs predominantly differentiate into ILC2s. Single-cell cultures demonstrate that
KLRG1+ ILCs can also differentiate into other ILC subsets depending on the signals they receive. Epigenetic profiling of KLRG1+
ILCs is consistent with the broad differentiation potential of these cells.
Introduction
Innate lymphoid cells (ILCs) exert their effector functions most
prominently in tissues, particularly at mucosal sites. ILCs are
rapidly activated by various stimuli produced by other immune
and nonimmune cells, and this allows for an efficient response to
the acute phase of infections and tissue damage (Artis and Spits,
2015; Ebbo et al., 2017). Consequently, ILCs are considered im-
portant in the maintenance and surveillance of mucosal integ-
rity. ILCs have been categorized into five subsets based on their
developmental trajectory, transcription factor (TF) require-
ments, and cytokine production profiles (Vivier et al., 2018).
These are natural killer (NK) cells, ILC1s, ILC2s, ILC3s, and
lymphoid tissue inducer cells. The ILC1, ILC2, and ILC3 subsets
derive from a common precursor and express CD127 (IL-7Rα;
Scoville et al., 2016); ILC1s are CD117− cells that produce IFN-γ
and depend on the TF T-bet; ILC2s express CRTH2, are capable of
producing IL-5 and IL-13, and depend on GATA3; and ILC3s are
CD117+ cells that can express natural cytotoxicity receptors, se-
crete IL-17 and IL-22, and require RAR-related orphan receptor
(ROR)γt.
In addition to mucosal surfaces, ILCs can also be found in
peripheral blood (PB). PB from healthy individuals consists of
CRTH2+ ILC2s, CD117−CRTH2− ILCs, and CD117+CRTH2− ILCs.
The CD117+CRTH2− population was recently shown to consist
of uni- and multipotent precursors of mature ILC1, ILC2, ILC3,
and NK-like cells (Lim et al., 2017). Consistent with their
differentiation potential, CD117+CRTH2− ILCs express high
levels of TFs that are essential for ILC development, such as
inhibitor of DNA binding protein 2 (ID2), GATA3, thymocyte
selection–associated high mobility group box protein (TOX),
and TF7 (TCF7). In contrast, moderate to low levels of the
lineage-determining TFs RORC, T-BOX 21 (TBX21), Eomeso-
dermin (EOMES), cytokine receptors, and signature cytokines
were found. A recent study provided additional information
on ILC subsets in general by broad analysis of ILC surface
antigen expression across several tissues and PB (Simoni
et al., 2017). This study confirmed and extended earlier
analyses of our group (Hazenberg and Spits, 2014; Mjo¨sberg
and Spits, 2016) that ILC2s and ILC3s can be characterized by
high expression of CD127 and CD161; additional expression of
CRTH2 and killer cell lectin-like receptor subfamily G mem-
ber 1 (KLRG1) identified ILC2s, whereas natural cytotoxicity
receptors NKp44, NKp46, and CD56 discriminate ILC3s
(Simoni et al., 2017). A detailed analysis of PB ILCs based on
the expression profiles reported in these studies may provide
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additional information on ILC heterogeneity and unravel their
developmental process.
In the present study, we performed a flow cytometric
analysis with an extensive panel of cell-surface markers and
observed that the CD117+CRTH2−NKp44− ILC population can
clearly be segregated by the expression of KLRG1 and NKp46.We
used a combination of gene expression profiling, epigenetic
analyses, and differentiation assays to address the develop-
mental status of these ILC subpopulations. These analyses
showed that KLRG1-expressing ILCs represent a developmen-
tally transitional stage of ILC2s, whereas the NKp46-expressing
ILCs relate to IL-22–producing ILC3s. Furthermore, a subgroup
of NKp46+ ILCs are capable of differentiation toward ILC1/NK-
like cells that produce IFN-γ.
Results
Hierarchical stochastic neighbor embedding (HSNE) analysis of
PB ILCs
Recent studies have shown that the CD117+ PB ILCs contain
multi- and unipotent ILC precursors (Lim et al., 2017; Chen et al.,
2018). Those observations prompted us to perform an extensive
flow cytometric analysis of CD117+CRTH2− ILCs in an attempt to
define subsets within this population. We analyzed blood lym-
phocytes from eight healthy donors by 13-color flow cytometry.
Single-cell suspensions were stained with a lineage (Lin) anti-
body cocktail (see Materials and methods) and multiple anti-
bodies against ILC-associated molecules. The Lin−CD94−CD127+
total ILC population was then analyzed by HSNE (van Unen
et al., 2017). This unbiased approach identified two major clus-
ters (A and B), of which cluster B could be subdivided into three
further subclusters (B1, B2, and B3), also in an unbiased matter.
The subclusters could be defined by the expression of NKp46,
CD56, and IL1R1, all ILC3-associated proteins (Cupedo et al.,
2009; Cella et al., 2010; Hughes et al., 2010; Scoville et al.,
2016; Fig. 1, A–C; and Fig. S1 A). Cells within cluster A uni-
formly expressed higher levels of CD127 and CD161; additionally,
they exclusively expressed CRTH2 and/or KLRG1 (Fig. 1, A and
B). Based on this analysis, we conclude that cluster A represents
PB ILC2s and cluster B contains ILC3-related cells. Interestingly,
although CRTH2 is reported to be the ILC2-defining marker, the
HSNE analysis suggested the presence of a CRTH2− ILC2 popu-
lation that expresses KLRG1 and has similar CD117 expression as
CRTH2+ ILC2s (Fig. 1 C). Subcluster B1 differed from B2 and B3
by lower CD117 and higher CD56 and NKp46 expression. How-
ever, cells in subcluster B1 were clearly distinct from
CD56+CD127− NK cells, as they have higher expression of CD117
and CD200R, similar to CD56−CD127+ ILCs (Fig. S1 B). Previously,
it was demonstrated that CD200R distinguishes mouse ILC1s
from NK cells (Weizman et al., 2017). Here, we demonstrate that
CD200R is expressed not only on ILC1s but also on all PB ILCs,
indicating that this marker discriminates all human ILC subsets
from NK cells. The CD56+CD200R+ ILCs are probably similar to
the CD56+ ILCs that were recently described in tonsils to give
rise to NK cells, ILC1s, and ILC3s (Chen et al., 2018). HSNE
analysis of total CD127+ ILCs in tonsil confirmed the presence of
all PB ILC subsets as well as NKp44+ ILC3s (Fig. S1 C).
CRTH2−CD117+ ILCs enclose KLRG1+ and NKp46+ populations
The four distinct ILC populations in PB, identified by HSNE
analysis, were resolved by classical flow cytometry to better
visualize low-frequency cell populations. Cluster A clearly con-
tained KLRG1-expressing cells that lack CRTH2 (Fig. 1 C). After
segregating the major ILC subsets by CD117 and CRTH2,
CD117+CRTH2− ILCs were further analyzed for expression of
NKp46, KLRG1, and CD56, which separated them into four
populations (Fig. 1 D). The four ILC populations were identified
as: KLRG1+NKp46−CD56− (KLRG1+ ILCs), KLRG1−NKp46−CD56−
(NKp46− ILCs), KLRG1−NKp46+CD56− (NKp46+ ILCs), and
KLRG1−NKp46+CD56+ (CD56+ ILCs), which uniformly express
CD7 in line with previously reported phenotypes (Fig. 1 D; Lim
et al., 2017). KLRG1+ ILCs did not express IL1R1, whereas NKp46+
ILCs and some NKp46− ILCs expressed this receptor, verifying
the HSNE analysis (Fig. 1, D and E). KLRG1+ ILCs and ILC2s
showed similar expression of CD127, CD161, and CCR6, sup-
porting the notion that KLRG1+ ILCs are more related to ILC2s
than to ILC3s (Fig. 1 E). Analysis of ILC subset frequency showed
that NKp46+ ILCs were most prevalent (52% of all PB
CD117+CRTH2− ILCs), followed by CD56+ ILCs (33%), NKp46−
ILCs (9%), and KLRG1+ ILCs (5%). All populations could be de-
tected in all donors (Fig. 1 F).
These CD117+CRTH2− ILC populations were not only present
in PB but also in inflamed tonsils and nasal polyp (NP) tissue
from patients with chronic rhinosinusitis (CRS; Figs. 1 G and S1
D). ILC3s are enriched in tonsils, while ILC2s are dominant in NP
(Mjo¨sberg et al., 2011). Unlike PB, these tissues contain NKp44-
expressing ILC3s, which coexpress NKp46 and partly CD56 (Figs.
1 G and S1 D). KLRG1+ ILCs were present exclusively in the
NKp44−NKp46− population, although the frequency was clearly
higher in NPs as compared with tonsils, which may reflect the
frequency of ILC2 in these tissues (Figs. 1 G and S1 E).
The expression pattern of CRTH2, KLRG1, NKp46, and NKp44
defines different developmental stages of ILCs
To characterize the KLRG1+ ILCs and NKp46+ ILCs inmore detail,
we evaluated the expression of ILC2 and ILC3 signature TFs. As
expected, all PB ILCs expressed GATA3. In addition, all PB ILCs
expressed low levels of RORC (Fig. 2 A). Both NKp44−NKp46+
ILC3s and NKp44+NKp46+ ILC3s from tonsil expressed very low
levels of GATA3 but high levels of RORC (Fig. 2 A). To assess the
differentiation capacity of KLRG1+ ILCs and NKp46+ ILCs, we
used a stromal cell–based culture system that supports ILC ex-
pansion and differentiation (Lim et al., 2016, 2017; Scoville et al.,
2016). Isolated KLRG1+ ILCs and NKp46+ ILCs were cultured on
OP9 cells, which either did or did not express the Notch ligand
delta-like (DL)1. To evaluate their unbiased developmental ca-
pacity, only IL-2 and IL-7 were added without additional in-
flammatory cytokines. After 5 d of culture, GATA3 was detected
in KLRG1+ ILCs regardless of the presence of a Notch ligand,
whereas RORγt was strongly up-regulated in NKp46+ ILCs in a
Notch-signaling–dependent manner (Fig. 2, B–D). Further cul-
tures were performed on OP9-DL1 cells, as these cells promoted
the differentiation of both ILC2s and ILC3s. In this setting, we
observed that besides the lineage-determining TFs, KLRG1+ ILCs
from PB and NP were able to up-regulate CRTH2, whereas
Nagasawa et al. Journal of Experimental Medicine 2
KLRG1 and NKp46 define subsets of human CD117+ ILCs https://doi.org/10.1084/jem.20190490
NKp46+ ILCs did not (Fig. 2, E and F; and Fig. S2 A). CRTH2
expression was not consistently up-regulated on KLRG1+ ILCs in
each donor. The reason for the heterogeneity is unclear, but we
noted that in those donors from whom the KLRG1+ ILCs failed to
up-regulate CRTH2, this receptor was down-regulated when
CRTH2+ ILC2s were cultured under the same conditions
(Fig. 2 F). We also observed that the expression level of CRTH2,
induced on KLRG1+ ILCs, cultured with IL-2 and IL-7 was lower
than that of ILC2s (Fig. 2 F), suggesting that the experimental
conditions may not be optimal to support full CRTH2 induction.
NKp46+ ILCs from PB and NKp44− ILC3 from tonsil differ-
entiated into NKp44+ RORγt+ ILC3s (Fig. 2, E and F; and Fig. S2
B). KLRG1+ ILCs could also differentiate in some cases to RORγt+
ILCs, but these cells failed to up-regulate NKp44. In line with
previous observations showing that CD117+CRTH2− PB ILCs can
differentiate into NK-like cells (Lim et al., 2017), NKp46+ ILCs
cultured under this condition maintained NKp46 expression and
up-regulated CD56, and some of them gave rise to EOMES-
expressing cells (Fig. 2 F and Fig. S2 C). These EOMES+ cells
coexpressed CD94, but not RORγt, T-bet, or CD16 (Fig. S2, C and
D). We observed that tonsil NKp44− ILC3s, but not NKp44+
ILC3s, could also give rise to EOMES+ RORγt− cells (Fig. S2 B).
These in vitro–differentiated CD56+ cells are phenotypically
similar to ex vivo PB NKp46+CD56+ ILCs, as they express EOMES
and very low TBX21 (T-bet). As NKp46+CD56+ cells ex vivo lack
expression of Granzyme B (GZMB) and Perforin 1 (PRF1) and
express significantly higher levels of RORC than NK cells (Fig. S2
E), EOMES+NKp46+CD56+ cells are clearly different from con-
ventional NK cells.
KLRG1+ and NKp46+ ILCs are biased to differentiate into
mature ILC2s and ILC3s, respectively
Next, we characterized the transcriptomes of the KLRG1+ ILC
and NKp46+ ILC subsets by microarray analysis. Principal-
component analysis (PCA) based on the most variable genes
(interquartile range [IQR] >1.5) showed a clear separation of
KLRG1+ ILCs, NKp46+ ILCs, ILC2s, and tonsil NKp44− ILC3s and
NKp44+ ILC3s, although one donor of KLRG1+ ILCs clustered
more with ILC2s (Fig. 3 A and Table S1 A). Analysis of the most
differently expressed genes revealed that KLRG1+ ILCs and ILC2s
shared 108 genes that were expressed higher as compared with
NKp46+ ILCs, NKp44− ILC3s, and NKp44+ ILC3s, including RORα,
one of the TFs known to be essential for ILC2 development in
mice (Wong et al., 2012; Fig. 3, B and C; and Table S1 B). KLRG1+
ILCs and ILC2s also shared higher expression levels of IL9R (IL-9
receptor), IL17RB (IL-25 receptor), PTGER2 (prostaglandin E2
Figure 1. Characterization of PB ILCs. (A) HSNE analysis of
the ILC population in PB (n = 8). Total PB lymphocytes were
stained with antibodies against Lin (CD1a, CD3, CD4, CD5, CD14,
CD19, CD16, CD34, CD94, CD123, BDCA2, TCRαβ, TCRγδ, and
FcER1α) and ILC-related molecules as indicated. The Lin−CD127+
population (ILCs) was further analyzed to identify clusters based
on the expression of different cell-surface molecules. Two
clusters are indicated as A and B, and cluster B is subdivided into
three subclusters (B1, B2, and B3). (B) Heatmap of expression
intensity of cell-surface molecules on different ILC clusters.
(C) Zoom-in of cluster A by HSNE. The circle indicates a pop-
ulation that expresses KLRG1 but lacks CRTH2. (D) Gating
strategy for flow cytometric analysis of PB ILC subsets (three
upper plots) and histogram of CD7 and IL1R1 expression on ILC
subsets (bottom). (E) KLRG1, CD56, and IL1R1 expression
pattern on ILC subsets (three upper plots), and histogram
of several ILC associated cell-surface molecules on KLRG1+
ILCs (Lin −CD127+CD117+CRTH2 −NKp46 −KLRG1+), ILC2s
(Lin−CD127+CRTH2+), and NKp46+ ILCs (Lin−CD127+CD117+
CRTH2−CD56−NKp46+; bottom). Filled histogram represents
isotype control (CTRL). (F) Frequency of each subset indicated
within the CD117+ CRTH2− ILC population from PB (n = 9).
(G) Gating strategy used for flow cytometric analysis of ILC
subsets in NPs and tonsils. Data in D, E, and G are representa-
tive of at least three donors from at least three independent
experiments.
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receptor), and HPGD (15-hydroxyprostaglandin dehydrogenase),
all markers that are typically associated with the ILC2 lineage
(Fig. 3, B and C; Turner et al., 2013; Bjo¨rklund et al., 2016). The
similarity of ILC2s and KLRG1+ ILCs was further emphasized by
the observation that only 22 genes were significantly differently
expressed (Fig. 3 D and Table S1 C). KLRG1+ ILCs had signifi-
cantly lower expression of CRLF2 (TSLP receptor), FCRL3, and
HPGDS, all genes that have been previously associated with
ILC2s (Bjo¨rklund et al., 2016; Gury-BenAri et al., 2016). This
could be a consequence of the lower GATA3 expression in KLRG1+
ILCs (Fig. 2 A), since these genes were suggested to be targets of
GATA3 (Bjo¨rklund et al., 2016). KLRG1+ ILCs had significantly
higher expression of two chemokine genes, XCL2 and CCL5
(RANTES); ANK1 (Ankyrin-1, a membrane protein), which plays
a role in cell stability and mobility; CR1L (complement compo-
nent receptor 1-like protein); and LST1 (lymphocyte-specific
transcripts 1), which can inhibit the proliferation of lymphocytes
(Fig. 3 D). Expression of IL-5 and IL-13, ILC2 signature cytokines,
was not detected in KLRG1+ ILCs nor in ILC2s. This indicates that
these cells are in a resting state and produce these cytokines only
after activation, as has also been demonstrated for tonsil ILC2s
(Bjo¨rklund et al., 2016). It is unlikely that the KLRG1+ ILCs
are either exhausted or ex-ILC2s, as the expression of ILC2
exhaustion markers, as described by Miyamoto et al. (2019),
does not differ between ILC2s and KLRG1+ ILCs (Fig. 3 E). Ad-
ditionally, both express CD62L and CD45RA, which are ex-
pressed on resting ILCs (Fig. 3 F; Bar-Ephraim et al., 2019).
We found 138 genes, shared by NKp46+ ILCs and NKp44− and
NKp44+ ILC3s from tonsils, that were significantly higher ex-
pressed as compared with ILC2s and KLRG1+ ILCs (Fig. 3 B).
These included ILC3-associated TFs, such as TOX, TOX2, and
RUNX2, and the cell-surface markers IL1R1, TNFRSF18 (GITR),
TNFRSF4 (OX40), and TNFSF11 (receptor activator of nuclear
factor kappa-Β ligand [RANKL]; Fig. 3, B and C; and Table S1 D;
Bjo¨rklund et al., 2016; Gury-BenAri et al., 2016; Bar-Ephraim
et al., 2017). NKp46+ ILCs and the two tonsillar ILC3 pop-
ulations also shared the expression of genes associated with
antigen presentation (CD74, HLA-DRA, HLA-DPA1, HLA-DMB, and
HLA-DMA; Fig. 3 B and Table S1 D).
PB NKp46+ ILCs are more similar to tonsil ILC3s as compared
with PB KLRG1+ ILCs. However, a more in-depth comparison of
NKp46+ ILCs to NKp44− ILC3s and NKp44+ ILC3s from tonsils
revealed that they are still very distinct from tonsil NKp44−
ILC3s and NKp44+ ILC3s (34 and 8 shared genes, respectively).
This is in stark contrast with NKp44− ILC3s and NKp44+ ILC3s,
which share expression of 664 genes (Fig. 3 G and Table S1 E).
Figure 2. Differentiation capacity of KLRG1+ ILCs
and NKp46+ ILCs. (A) Quantification of relative GATA3
and RORC expression as compared with GAPDH in dif-
ferent ILC subsets isolated from tonsils and PB.
(B) Representative histograms of GATA3 and RORγt
expression in KLRG1+ ILCs and NKp46+ ILCs, respec-
tively, after culture for 5 d on OP9 or OP9-DL1 in the
presence of IL-2 (20 U/ml) and IL-7 (20 ng/ml).
(C) Quantification of GATA3 expression on KLRG1+ and
NKp46+ ILCs after culture as in B. (D) Quantification of
RORγt expression on KLRG1+ and NKp46+ ILCs after
culture as in B. (E) Representative flow cytometric
analysis of CRTH2, GATA3, NKp44, and RORγt expres-
sion on KLRG1+ ILCs, ILC2s, and NKp46+ ILCs after cul-
ture for 5 d on OP9-DL1 in the presence of IL-2 (20 U/ml)
and IL-7 (20 ng/ml). (F) Quantification of the percentage
of cells expressing CRTH2, NKp44, GATA3, RORγt,
EOMES, and T-bet upon culture as in E. Each dot rep-
resents one individual donor. *, P < 0.05; **, P < 0.001;
***, P < 0.0001; ****, P < 0.00001 (one-way ANOVA).
Data in B and E are representative of at least three
donors from at least three independent experiments.
AU, arbitrary units; CTRL, control; MFI, mean fluores-
cence intensity.
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NKp46+ ILCs have higher expression of genes that are important
for development of ILC3s such as NFIL3 and GATA3 as well as
TNFRSF11A (RANK), a receptor regulating ILC3 suppression
(Fig. 3 H and Table S1 F; Bando et al., 2018). NKp44− and NKp44+
ILC3s from tonsils expressed higher levels of RORC and the
prototypical ILC3 markers IL23R, CD2, TNFSF4 (OX40L), and
TNFSF10 (TNF-related apoptosis-inducing ligand [TRAIL]),
indicating that these cells are mature ILC3s. Only tonsillar
NKp44+ ILC3s expressed high levels of IL22, IL26, and TNFSF13B
(B-cell activating factor [BAFF]), suggesting that these cells were
activated in situ (Bar-Ephraim et al., 2017). These NKp44+ ILC3s
also expressed higher levels of the chemokine receptors CCR6,
CXCR6, and CXCR5 and the lymphoid tissue inducer cell marker
NRP1 (Shikhagaie et al., 2017). Interestingly, PB NKp46+ ILCs and
Figure 3. Microarray analysis of KLRG1+ ILCs, NKp46+ ILCs, ILC2s, tonsil NKp44− ILC3s, and NKp44+ ILC3s. (A) PCA plot of gene expression as de-
termined by microarray in KLRG1+ ILCs, ILC2s, NKp46+ ILCs, tonsil isolated NKp44− ILC3s, and NKp44+ ILC3s; three donors each). (B) Heatmap of significantly
different expressed genes associated with ILC2s and ILC3s. (C) Log2 expression showing the expression values of selected genes. (D) Heatmap of significantly
differently expressed genes between KLRG1+ ILCs and ILC2s (left) and log2 expression of HPGDS and CRLF2 (right). (E) Heatmap of expression of genes related
to ILC2 exhaustion. (F) Representative histograms of expression of CD62L and CD45RA on KLRG1+ ILCs, NKp46+ ILCs, and ILC2s. (G) Venn diagram showing
genes that are up-regulated in NKp46+ ILCs, tonsil NKp44− ILC3s, and tonsil NKp44+ ILC3s. (H) Heatmap of significantly different expressed genes between
NKp46+ ILCs, tonsil NKp44− ILC3s, and tonsil NKp44+ ILC3s. Data in F are representative of at least three donors from at least three independent experiments.
PC, principal component; HLA-DRA, human leukocyte antigen DR alpha; HLF, hepatic leukemia factor; HPGD, 15-hydroxyprostaglandin dehydrogenase; HPGDS,
hematopoietic prostaglandin D synthase; KIT, proto-oncogene, receptor tyrosine kinase; RORA, RAR-related orphan receptor.
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NKp44− ILC3s shared high expression of S1PR1,which is involved
in ILC migration (Bjo¨rklund et al., 2016; Bar-Ephraim et al.,
2017). Altogether, these data show that KLRG1+ ILCs are more
similar to ILC2s and NKp46+ ILCs to ILC3s, although genes as-
sociated with key functions of mature ILC3s, including signature
cytokines, are not expressed in NKp46+ ILCs.
KLRG1+ ILCs and NKp46+ ILCs can produce multiple cytokines
when stimulated with inflammatory cytokines
KLRG1+ ILCs and NKp46+ ILCs do not produce cytokines in the
differentiation cultures with IL-2 and IL-7. To evaluate the
functional capacities of KLRG1+ ILCs and NKp46+ ILCs, we co-
cultured these ILCs and ILC2s from PB for 7 d on OP9-DL1 cells in
the presence of different inflammatory cytokines. KLRG1+ ILCs
and ILC2s up-regulated the ILC2-related activation molecule
CD25 (Mjo¨sberg et al., 2011) in response to TSLP and IL-33,
whereas NKp46+ ILCs did not (Fig. 4, A and B). In contrast, the
ILC3-associated molecule RANKL was specifically up-regulated
only on NKp46+ ILCs in response to IL-1β and IL-23 (Fig. 4, A and
B). In addition, both KLRG1+ ILCs and ILC2s produced IL-5 and
IL-13 not only upon culture in the presence of TSLP and IL-33 but
also in response to IL-1β and IL-23, although TSLP with IL-33
was a more potent inducer of these cytokines (Fig. 4, C and D).
Interestingly KLRG1+ ILCs cultured on OP9-DL1 cells with IL-
1β and IL-23 secreted not only IL-5 and IL-13 but also IFN-γ, IL-
22, IL-17A, and GM-CSF (Fig. 4, C and D; and Fig. S2 F). Low
amounts of IL-17A were also produced by ILC2s, but ILC2s pro-
duced no IFN-γ and IL-22 when stimulated with IL-1β and IL-23
(unlike KLRG1+ ILCs).
NKp46+ ILCs did not respond to IL-33 and TSLP or produce
IL-5 and IL-13 but secreted IFN-γ, IL-22, and low amounts of IL-
17A and GM-CSF upon IL-1β and IL-23 stimulation when cul-
tured on OP9-DL1 (Fig. 4, C and D; and Fig. S2 F). The production
of IFN-γwas increased upon culture of both NKp46+ and KLRG1+
ILCs with IL-1β and IL-12 (Fig. 4 E). This was accompanied by
down-regulation of CD117 and NKp44 expression, indicating that
these cells transdifferentiated into ILC1s in response to IL-12, as
we have previously shown for CRTH2+ ILC2s and NKp44+ ILC3s
(Fig. 4 F; Bernink et al., 2015; Bal et al., 2016). EOMES, T-bet, and
CD94 were up-regulated in all PB ILC populations upon culture
with IL-1β and IL-12, suggesting that this culture condition in-
troduces NK cell features in all ILC subsets (Fig. 4, F and G).
Clonal analysis of CD117+ PB ILC subsets shows broad
functional differentiation capacities
The observation that KLRG1+ ILCs produced type 1, 2, and 3
cytokines following stimulation with IL-1β and IL-23 raised the
possibility that IL-1β and IL-23 promote differentiation of
KLRG1+ ILCs into multiple ILC subsets. Alternatively, the KLRG1+
ILCs may contain mixtures of clones with different precursor
activities. To address this, we single-cell sorted KLRG1+ ILCs,
NKp46+ ILCs, and ILC2s and cultured them on OP9-DL1 in the
presence of IL-2, IL-7, IL-1β, and IL-23, as this culture condition
promoted differentiation of all three PB ILC populations into
cytokine-producing ILC subsets (Fig. 4, C and D). After 2 wk,
with a cloning efficiency of ∼13%, all three subsets gave rise to
cytokine-producing ILCs. From the 110 KLRG1+ ILC clones, 81
were evaluated for their cytokine production, surface protein,
and TF expression. The cytokine production pattern differed
among clones, and clones could be divided into single-, dual-, or
multicytokine producers (Fig. 5 A). 68 clones (84%) produced IL-
13; and 52 clones (64%) produced both IL-5 and IL-13, of which 38
(47%) did not coproduce other cytokines. These data indicate
that most of the KLRG1+ ILC differentiated into IL-5– and
IL-13–producing ILC2s. However, IL-17A–, IFN-γ–, and IL-
22–producing clones were also detected, most of which copro-
duced IL-5 and/or IL-13, indicating that these cells retain ILC2
features but are more flexible (Fig. 5, A and B). A small minority
of the KLRG1+ ILC-derived clones expressed only IFN-γ. IL-13
production correlated with GATA3 expression and IL-22 pro-
duction with EOMES expression (Figs. 5 C and S3 A). ILC2s re-
tained their ILC2 fate in response to IL-1β and IL-23, as 96% of
ILC2s produced IL-13 and IL-5 and only 7% coproduced IL-17 or
IFN-γ and no IL-22–producing clones were obtained (Fig. 5 B).
Analysis of the clones derived from NKp46+ ILCs revealed
that the majority of clones produced IL-22 (82%) and a major
part of IL-22 producing clones also coproduced IFN-γ (45%).
Only a few clones (5%) produced IL-17A, confirming the results
obtained in bulk cultures (Fig. 5, D and F). IFN-γ single-
producing clones (15%) were also observed in this culture. No
GATA3 was detected in any clones, similar to what we observed
in the bulk culture, and RORγt was expressed in this culture
condition (Fig. 5 E). Coexpression of RORγt, T-bet, and EOMES
could be detected in clones coproducing IL-22 and IFN-γ, indi-
cating that EOMES is not uniquely specific for human NK cells,
at least under in vitro conditions. We also observed that IFN-γ
single-producing clones are heterogeneous in terms of TF pro-
files, as they showed various combinations of RORγt, EOMES,
and T-bet expression (Fig. S3 B). These results indicate that the
majority of NKp46+ ILCs differentiated into IL-22–producing
ILC3s, and some of them acquired IFN-γ production capacity.
Not all IFN-γ–producing clones showed characteristics of ILC1/
NK-like cells; instead, they displayed an intermediate ILC3-
ILC1/NK-like phenotype. Collectively, our data suggest that
KLRG1+ ILCs belong to the ILC2 lineage, whereas NKp46+ ILCs
are skewed to ILC3s.
As the CD117+ ILC population also included a small popula-
tion that did not express NKp46 or KLRG1, this population
might contain a more upstream precursor that can give rise to
both the KLRG1+ ILCs and NKp46+ ILCs. Indeed, bulk and clonal
cultures revealed that this population was able to respond to IL-
33/TSLP and IL-1β/IL-23. Clonal cultures with IL-1β and IL-23
resulted in production of IL-5, IL-13, IL-17A, IL-22, and IFN-γ
(Fig. S3, C–E).
Unique epigenetic features of KLRG1+ ILCs support their
immature state
The different gene expression and functional differentiation
capabilities of KLRG1+ ILCs and ILC2s is likely reflected by dif-
ferences in their epigenome, as epigenetic priming of gene
regulatory elements is linked to cellular plasticity (Stadhouders
et al., 2018). We therefore performed an assay for transposase-
accessible chromatin with high-throughput sequencing (ATAC-
seq; Buenrostro et al., 2013) to map genome-wide chromatin
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accessibility in KLRG1+ ILCs and ILC2s. We reproducibly de-
tected 26,192 accessible regions across both cell types of which
273 were uniquely or substantially more (>2.0-fold) active in
ILC2s and 474 in KLRG1+ ILCs (Fig. 6, A–C). Whereas many ILC2
signature genes, including RORA, GFI1, and Bcl11b, were associ-
ated with active chromatin both in ILC2s and KLRG1+ ILCs (Fig.
S4), genes typically associated with ILC2 functionality, including
the T helper type 2 cell (Th2 cell) cytokine locus, IL9, and GATA3,
had an active chromatin signature specific for ILC2s (Fig. 6, D–F;
and Fig. S4). Other enriched biological pathways in ILC2s in-
cluded prostaglandin metabolism (ANXA1, FABP5, HPGD, HPGDS,
and PNPLA8, in concordance with elevated HPGDS expression;
Figure 4. KLRG1+ ILCs and NKp46+ ILCs show multipotent cytokine production and TF profile. (A) Representative histogram of expression of CD25 or
RANKL on KLRG1+ ILCs, ILC2s, and NKp46+ ILCs after culture on OP9-DL1 cells in the presence of IL-2 and IL-7 with or without TSLP and IL-33 or IL-1β and IL-23
for 7 d. (B)Quantification of CD25 or RANKL expression on after culture as in A (n = 3–8). (C) Representative flow cytometric analysis of intracellular IL-5, IL-13,
IFN-γ, and IL-17A in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs, after 7 d culture as in A and subsequently stimulated by PMA/ionomycin for 3 h. (D)Quantification of
cytokine production by ELISA in culture supernatants from cells stimulated as in A. The concentration is adjusted to 5,000 cells. (E) Quantification of IFN-γ
production by ELISA of ILC subsets cultured on OP9-DL1 cells in the presence of IL-2 and IL-7 with IL-1β and IL-23 or IL-1β and IL-12 for 7 d. (F) Representative
flow cytometry of the expression of CD117, NKp44, and CD94 on KLRG1+ ILCs, ILC2, and NKp46+ ILCs after culture as in E. Filled histograms represent isotype
control. (G) Representative flow cytometric analysis of intracellular expression of EOMES and T-bet in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs after culture as in
E. Data in A, C, F, and G are representative of at least three donors from more than three independent experiments. Cytokines used in all experiments are IL-
2 (20 U/ml), IL-7, TSLP, IL-33, IL-1β, IL-23, and IL-12 (all 20 ng/ml). **, P < 0.001; ***, P < 0.0001; ****, P < 0.00001 (one-way ANOVA).
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Figure 5. Clonal analysis of CD117+ PB ILC subsets shows broad functional differentiation capacities. (A–E) Single KLRG1+ ILCs, ILC2s, or NKp46+ ILCs
from PB were index sorted by FACS into 96-well round-bottom plates preseeded with OP9-DL1 and stimulated with IL-2 (20 U/ml), IL-7, IL-1β, and IL-23
(20 ng/ml each). (A) After 14–21 d, KLRG1+ ILC cultures were analyzed for intracellular cytokine production (IL-5, IL-13, IFN-γ, IL-17A, and IL-22) after PMA/
ionomycin stimulation. Representative flow cytometric analysis of clones producing various combinations of cytokines as indicated. (B) Summary of numbers
and type of cytokines produced by KLRG1+ ILC clones and ILC2 clones. Three KLRG1+ ILC clones did not produce any of the measured cytokines. (C) Correlation
of IL-13 production with GATA3 expression and IL-22 production with EOMES expression in KLRG1+ ILCs. (D) Representative flow cytometric analysis of
NKp46+ ILC clones producing various combinations of cytokines as indicated. (E) Representative flow cytometric analysis of intracellular RORγt, T-bet, and
EOMES expression of selected clones obtained from NKp46+ ILCs upon culture as in A. (F) Summary of numbers and type of cytokines produced by NKp46+ ILC
clones. 28 NKp46+ ILC clones did not produce any of the measured cytokines. Data in A, C, and D are representative of at least four donors. MFI, mean
fluorescence intensity.
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Fig. 3 D) and T cell costimulation (e.g., ICOS and ICOSL; Fig. 6,
D–F and Fig. S4). We found that gene regulatory elements
bearing an active chromatin signature specific for KLRG1+ ILCs
were located near genes enriched for processes involved in the
differentiation of Th1, Th2, and Th17 cells (including IL23R,
IL12RB1/2, and IFNG). These findings support the immature
nature of the KLRG1+ ILCs and confirm our in vitro differenti-
ation assays. KLRG1+ ILCs also showed regulatory activity near
(TF) genes important for ILC development, such as TCF7 and
PDCD1. As expected, the KLRG1 locus harbored accessible chro-
matin in both ILC2s and KLRG1+ ILCs. In summary, our regulome
data are consistent with the data of the in vitro culture assays
Figure 6. Unique epigenetic features of KLRG1+ ILCs support their immature state. (A) Venn diagram showing the total number of ATAC-seq peaks (n =
26,192, detected in at least two replicate datasets) and the subsets uniquely or substantially more accessible (>2.0-fold) in either ILC subset. (B and C) PCA (B)
or hierarchical clustering (C) on the 747 differentially enriched ATAC-seq peaks defined in A. (D) Pathway enrichment analysis using the genes assigned to both
sets of differentially enriched ATAC-seq peaks. (E and F) Representative genome browser shots of ATAC-seq signals across selected loci (E); signals in
highlighted regions were quantified across the three biological replicate datasets generated (F). Error bars indicate SEM. PC, principal component; ICOS,
inducible T cell costimulator; ICOSLG, inducible T cell costimulator ligand; IFNG, interferon gamma; LCR, locus control region.
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indicating that KLRG1+ ILCs are immature and able to develop
into multiple ILC subsets.
Functionality of KLRG1+ILCs and NKp46+ILCs in tissues
As we identified populations phenotypically similar to KLRG1+
ILCs and NKp46+ ILCs in different tissues, we studied the cy-
tokine potential of these tissue-derived ILCs. Culture of KLRG1+
ILCs and ILC2s from NPs from CRS patients on OP9-DL1 cells
resulted in IL-13–producing cells (Fig. 7 A). In response to IL-
1β and IL-23, KLRG1+ ILCs clearly produced IFN-γ and low
amounts of IL-22, whereas NP ILC2s did not. In contrast to
KLRG1+ ILCs from blood, we hardly detected production of IL-
17A by NP KLRG1+ ILCs. NKp46+ ILCs from this tissue were not
able to produce either IL-13 or IL-17A but were able to produce
IL-22 and IFN-γ in response to IL-1β and IL-23 (Fig. 7 A).
Tonsil ILC3s are very distinct from PB NKp46+ ILCs, and in
response to IL-1β and IL-23, these cells were more potent IL-22
producers than PB NKp46+ ILCs. Tonsil ILC3s also produced low
levels of GM-CSF and IL-17 (Fig. 7, B and C). Interestingly,
whereas NKp44− ILC3 from tonsils produced high amounts of
IFN-γ, tonsillar NKp44+ ILC3s were poor IFN-γ producers (Fig. 7,
B and C). It should be noted that ex vivo–isolated tonsillar
NKp44− ILC3s did not produce IFN-γ, IL-22, and IL-17A, whereas
NKp44+ ILC3s produced IL-22, but not IFN-γ or IL-17A (Fig. S5, A
and B). In conclusion, this shows that tissues contain cells
phenotypically similar to circulating KLRG1+ and NKp46+ ILCs,
but these cells have probably already been imprinted in the
tissue and are more restricted to the ILC2 and ILC3 fate,
respectively.
Discussion
Recently, PB and tonsil CD34− CD117+ ILCs were described to
enclose cells that have the capacity to develop into multiple ILC
subsets (Lim et al., 2017; Chen et al., 2018). Our data indicate that
the CD117+ ILC population is heterogeneous and contains ILCs
that belong to either the ILC2 or ILC3 lineage. HSNE analysis
revealed the presence of PB ILCs that express KLRG1, known to
Figure 7. Functionality of KLRG1+ ILCs and NKp46+
ILCs in tissues. (A) Representative flow cytometric
analysis of intracellular IL-13, IL-17A, IFN-γ, and IL-22 in
KLRG1+ ILCs, ILC2s, and NKp46+ ILCs isolated from NPs,
cultured on OP9-DL1 cells in the presence of IL-2 (20 U/
ml) and IL-7 (20 ng/ml) with or without IL-1β and IL-23
(20 ng/ml each) for 7 d, and subsequently stimulated by
PMA/ionomycin for 3 h. (B) Representative flow cyto-
metric analysis of intracellular IL-13, IL-17A, IFN-γ, and
IL-22 in NKp44−NKp46+ ILC3s and NKp44+NKp46+
ILC3s isolated from tonsils, cultured and stimulated as in
A. (C) Quantification of cytokine production by ELISA in
culture supernatants from cells stimulated as in A. The
concentration is adjusted to 5,000 cells. Data in A and B
are representative of at least three donors from three
independent experiments.
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be present both on mouse (Hoyler et al., 2012) and human ILC2s
(Salimi et al., 2013; Simoni et al., 2017), but lack the human ILC2
marker CRTH2. We propose that these KLRG1+ILCs are pre-
cursors of ILC2s, because they are transcriptionally similar to
CRTH2+ ILC2s but express relatively low levels of cytokine re-
ceptors and genes involved in ILC2 functionality. KLRG1+ ILCs
express less GATA3 and its putative targets HPGDS and FCRL3
than ILC2s and have less accessible chromatin regions that are
associated with ILC2-specific genes. Importantly these cells can
differentiate into cytokine-producing CRTH2+ ILC2s in vitro.
Whereas KLRG1+ ILCs and ILC2s produce similar amounts of
IL-5 and IL-13 upon activation with TSLP and IL-33, a proportion
of KLRG1+ ILCs could acquire the capacity to produce IL-17A, IL-
22, and IFN-γwhen cultured with IL-1β and IL-23. This is similar
to the ILC precursors described by Lim et al. (2017). These re-
searchers demonstrated that CD117+ PB ILCs contain clones that
are able to produce multiple cytokines upon culture with IL-2,
IL-7, IL-1β, and IL-23. We showed that among those CD117+ PB
ILCs, only KLRG1+ ILCs and KLRG1− NKp46− ILCs have this ca-
pacity. As the KLRG1+ ILCs produced type 2 cytokines, but not
type 3 cytokines, upon culture with IL-33 and TSLP, the differ-
entiation capacity of this subset depends on the kind of stimulus.
Our findings therefore strongly suggest that the KLRG1+ ILCs are
transitional cells that are biased to, but not yet fully committed
to, the ILC2 fate. Indeed, our ATAC-seq analysis of KLRG1+ ILCs
revealed epigenetic priming at loci associated with functionally
different ILC fates, providing a molecular mechanism for the
observed differentiation of KLRG1+ ILCs.
KLRG1 is also expressed by mouse ILC2s, although high ex-
pression was only observed after stimulation with IL-25 or upon
Nippostrongylus brasiliensis infection. These mouse KLRG1hi ILC2s
were called inflammatory (iILC2s) and appeared to play an im-
portant role in the host defense during infection. iILC2s were
shown to be highly migratory cells as compared with IL-
33–responsive KLRG1dim natural ILC2s. Interestingly, mouse
iILC2s were multipotential and are able to differentiate into IL-
17–producing ILC3-like cells and natural ILC2s (Huang et al.,
2015, 2018). The KLRG1+ ILCs described here bear similarities
with mouse iILC2s, as they express KLRG1 and can acquire the
capacity of producing IL-17.
We also observed that the PB ILC population can be further
segregated into three populations based on their expression of
NKp46 and CD56. NKp46+ ILCswere able to differentiate into IL-
22–producing ILC3s upon culture with OP9-DL1, IL-1β, and IL-
23. The NKp46+ ILCs do not have the capacity to differentiate
into ILC2s, suggesting that NKp46+ ILCs are comparable to the
CD56+ NKp46+ ILCs described by Chen et al. (2018). The PB
NKp46+ ILCs do not express cytokines when isolated ex vivo and
share similarities with NKp44− ILC3s isolated from resting sec-
ondary lymphoid organs (SLOs), except that the latter cells ex-
press more RORγt and IL23R than the former (Bar-Ephraim
et al., 2017). Both PB NKp46+ ILCs and NKp44− SLO ILC3s ex-
pressed higher migratory related genes such as S1PR1 (Bar-
Ephraim et al., 2017). However, NKp44− ILC3s from SLOs are
capable of producing cytokines upon IL-1β and IL-23 stimulation
without Notch signaling (Bar-Ephraim et al., 2017). The notion
that RORγt was only induced in NKp46+ ILCs upon Notch
signaling suggests that peripheral S1PR1-expressing NKp46+
ILCsmaymigrate into tissues and require signals from the tissue
microenvironment to become functional ILC3s. Freshly isolated
PB NKp46+ ILCs expressed high levels of GATA3, and although
this TF is associated with ILC2 development and function, it is
also required for ILC3 development (Serafini et al., 2014; Zhong
et al., 2016). The high GATA3 levels may be responsible for the
low RORC expression in NKp46+ ILCs as compared with NKp44+
ILC3s, as it is known that RORγt is negatively regulated by
GATA3 at an early stage of development (Zhong et al., 2016). As
the frequency of IL-17–producing NKp46+ ILCs is low, we con-
clude that they are biased mainly toward IL-22. These in vitro–
differentiated ILC3s are therefore very similar to the mouse
CCR6− NKp46+ ILC3s that in response to IL-23 are potent IL-22–
and IFN-γ–producing ILC3s but lack IL-17 potential (Klose et al.,
2013).
Some of the NKp46+ ILCs in PB coexpressed CD56. These cells
are most likely not NK cells, because they express CD127 and
CD117 and lack CD16 and CD94 expression. Moreover, the CD56+
cells expressed CD200R, which was recently found to be ex-
pressed on mouse ILC1s, but not on NK cells (Weizman et al.,
2017). Human ILC2s also express CD200R (Blom et al., 2017), and
here, we show that this marker is expressed on all ILC subsets.
The CD56+NKp46+ ILCs are most likely derived from NKp46+
ILCs, because these ILCs up-regulated CD56 in the differentia-
tion cultures and CD56+ ILCs could also give rise to IL-22– and
IFN-γ–producing cells (Chen et al., 2018). This is consistent with
a previous report on CD56 expression on IL-22 producing ILC3s
(Cella et al., 2009). As reported earlier (Lim et al., 2017; Chen
et al., 2018), there is a link between NKp46+ ILCs and NK cells,
because both NKp46+ ILCs and ILC3s seem to possess the po-
tential to differentiate into NK cells, particularly when cultured
with IL-12 or IL-15 (Kyoizumi et al., 2017; Raykova et al., 2017).
Whether this means that these NKp46+ ILCs represent an
obligatory transitional cell type in NK cell development remains
unclear. It should, however, be noted that the NKp46+ ILCs ex-
pressed high levels of CD117, and because CD117high ILCs are
absent in RORC-deficient patients (Okada et al., 2015), it is likely
that NKp46+ ILCs are absent in these patients. In contrast, NK
cell numbers in these patients are in the normal range, strongly
suggesting that NK cell development can proceed in the absence
of NKp46+ ILCs. It is, however, possible that NK cell develop-
ment via NKp46+ ILCs is an alternative pathway. It is in this
context noteworthy that KLRG1+ ILCs and ILC2s also differen-
tiated into EOMES and CD94-expressing NK-like cells and ILC1s
in the presence of IL-1β and IL-12 (Bal et al., 2016; Silver et al.,
2016).
As stated above, CD117high ILCs are absent in patients with
deficiencies in RORC (Okada et al., 2015). Although we were
unable to verify this, we speculate that the CD117dim cells, which
are still present in RORC-deficient patients, are identical to the
KLRG1+CD117+ ILCs identified here, since Lim et al. (2017) ob-
served that the CD117dim cells from RORC-deficient patients can
develop into ILCs that can produce both type 2 cytokines and the
type 3 cytokine IL-22 (but not IL-17, which requires RORγt)
when cultured on OP9-DL with IL-2, IL-7, IL-1β, and IL-23 (Lim
et al., 2017). These data are consistent with our observation that
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KLRG1+ ILCs, while preferentially developing into ILC2s, can
under inflammatory conditions also differentiate into ILCs with
a broader cytokine secretion profile. We show that the re-
maining CD117+NKp46−KLRG1−IL1R1+/− population, which rep-
resents ∼5% of the CD117+ ILC population in the PB, have the
capacity to develop to all ILCs. Importantly, these cells lack
CD34, which is expressed on hematopoietic stem cells and
committed precursors. For instance, human pre-T cells, (pre)
pro-B cells, and myeloid precursors all express CD34. Indeed,
committed ILC3 precursors and common ILC/NK precursors
identified in human SLOs and intestinal lamina propria express
CD34 (Montaldo et al., 2014; Scoville et al., 2016). It still remains
to be studied how CD34+ ILCs give rise to the circulating CD117+
ILC subsets that eventually develop into mature ILCs.
Collectively, our results indicate that KLRG1+ ILCs are tran-
sitional cells that are biased to differentiate into ILC2s but under
inflammatory conditions are able to produce multiple ILC sig-
nature cytokines. Moreover, NKp46 clearly defines ILC3-
lineage–biased cells that retained the capacity to differentiate
into ILC1s in the presence of IL-12, like KLRG1+ ILCs, but are
unable to develop into ILC2s.
Materials and methods
Human blood and tissue samples
Buffy coats were provided by the blood bank (Sanquin, Am-
sterdam). Tonsils were obtained from routine tonsillectomies,
and tissue collection was done at the Academic Medical Center
(AMC), Onze Lieve Vrouwe Gasthuis Hospital (Amsterdam, The
Netherlands). Inflamed NPs were obtained from CRS patients
during surgery, and umbilical cord blood was collected at the
AMC. The collection and use of all human samples was approved
by the Medical Ethical Committee of the AMC and with in-
formed consent.
Isolation of ILCs from blood and tissues
Peripheral blood mononuclear cells were isolated by Ficoll-
Hypaque density gradient (Lymphoprep; Axis-Shield). Ton-
sil tissue was cut in fine pieces and mechanically disrupted
using the Stomacher 80 Biomaster. Cell suspensions were
filtered through a 70-µm cell strainer. Nasal tissues were
manually cut into fine pieces and digested for 45 min at 37°C
with Liberase TM (125 µg/ml) and DNase I (50 U/ml). Cell
suspensions were filtered through a 70-µm cell strainer.
Mononuclear cells were then isolated by Ficoll-Hypaque
density gradient. Subsequently, ILCs were isolated as de-
scribed previously (Krabbendam et al., 2018). Briefly, PB and
cord blood were enriched for ILCs by immunomagnetic cell
sorting using a negative selection of CD3, CD14, CD16, and
CD19 with the Mojosort magnetic cell separation system (Bio-
Legend). Tonsillar mononuclear cells were depleted of CD3 and
CD19 cells by magnetic cell sorting (MACS) depletion. The cell
suspensions were stained with antibodies against lineage
(CD1a, CD3, CD4, CD5, CD14, CD19, CD16, CD34, CD94, CD123,
BDCA2, TCRαβ, TCRγδ, and FcER1α), CD45, CD161, CD127,
CD117, CRTH2, KLRG1, NKp44, NKp46, CD56, and IL-1R1. De-
tailed information about antibodies and other reagents can be
found in Table S2. Cells were sorted on a FACSAria, and purity
of the sorted cells in all experiments was >99%.
Flow cytometry analysis
For experiments involving intracellular cytokine staining, cells
were stimulated with PMA (10 ng/ml; Sigma) plus Ionomycin
(500 nM; Merck) in the presence of Golgi Plug (BD Biosciences)
for 3 h at 37°C. For FACS analysis, cultured cells were washed
with PBS and stained with fixable viability dye eFluor 455UV
(eBioscience) for 30 min at 4°C in PBS, followed by cell-surface
antigen staining with antibodies for 20 min at 4°C in PBS. Then
cells were fixed and permeabilized using the Foxp3/Transcrip-
tion Factor Staining Buffer Kit (Thermo Fisher Scientific), and
intracellular cytokines were stained with antibodies for 30 min
at room temperature in permeabilization buffer. Samples were
acquired on LSRFortessa or FACSCanto II (BD Biosciences) and
analyzed with FlowJo software and Cytosplore+HSNE (van Unen
et al., 2017).
Cell lines and ILC bulk and single-cell co-culture with OP9 cells
The naive OP9 murine stromal cell line was kindly provided by
Dr. T. Nakano (Osaka University, Osaka, Japan). OP9-DL1 cells
were generated as previously described (Dontje et al., 2006).
Ex vivo–isolated ILCs were co-cultured with OP9 or OP9-DL1 in
Yssel’s medium (IMDM supplemented with 4% [vol/vol] Yssel’s
supplement (made in-house; AMC) and 2% [vol/vol] human AB
serum [Invitrogen]). OP9 or OP9-DL1 cells (3,000 cells in 100 µl
Yssel’s medium per well in 96-well round-bottom plates) were
plated 1 d before co-culture. Bulk ILCs (100–1,000 cells) were
cultured for 5–10 d with combinations of IL-2 (20 U/ml), IL-7, IL-
33, TSLP, IL-1β, IL-23 (all at a concentration of 20 ng/ml), and
cytokines were supplemented on day 5. For single-cell cloning
experiments, cytokines and medium were replenished once per
week, and cells were analyzed after 2–3 wk.
Microarray analysis
To isolate total RNA, sorted cells were flash frozen in PBS
immediately after sorting and stored at −80°C before RNA
extraction. QIAzol Lysis Reagent (Qiagen) was added to the
cells, and RNA was isolated and purified using the RNeasy kit
(Qiagen). The concentration was measured on a NanoDrop
ND-2000 (Thermo Fisher Scientific), and RNA integrity was
examined using the 2200 TapeStation System with Agilent
RNA ScreenTapes (Agilent Technologies). Total RNA was
amplified using the GeneChip WT Pico Kit (Thermo Fisher
Scientific) generating biotinylated sense-strand DNA targets.
The labeled samples were hybridized to human Clariom S pico
arrays (Thermo Fisher Scientific). Washing and staining was
performed using the GeneChip Fluidics Station 450, and
scanning was performed using the GeneChip Scanner 3000
(both Thermo Fisher Scientific). All cell populations were
generated in triplicate. All data analysis was performed in
RStudio. Raw data were normalized using the robust multi-
array average (RMA) algorithm implemented in the limma
Bioconductor R-package (Ritchie et al., 2015). Adjusted
P values were calculated using the Benjamini–Hochberg
method. Data were visualized using glimma and pheatmap R
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packages (Su et al., 2017). The R package UpsetR was used to
visualize cloning experiments (Lex et al., 2014).
Quantitative real-time PCR
Total RNA was extracted with a NucleoSpin RNA XS kit
(Macherey-Nagel) according to the manufacturer’s instructions.
cDNA was synthesized with a High-Capacity cDNA Archive kit
(Applied Biosystems). PCRswere performed in a Bio-Rad iCycler
with IQ SYBR Green Supermix (Bio-Rad). The primer sets used
are listed in Table S2. Bio-Rad CFX Manager 3.1 software was
used for quantification of expression. All samples were nor-
malized to the expression of GAPDH, and results are presented
in arbitrary units.
ATAC-seq
ATAC-seq was performed as previously described (Buenrostro
et al., 2013) with minor modifications. Cells from three donors
were sorted (as described above; 20,000 ILC2s and ∼2,000
KLRG1+ILCs per donor) in freshly prepared cold ATAC-seq lysis
buffer (10 mMTris-HCl, pH 7.5, 60mMKCl, 15 mMNaCl, 5 mM
MgCl, 0.1 mM EGTA, 0.3 M sucrose, 0.1% NP-40, 0.15 mM
spermine, 0.5 mM spermidine, and 2 mM 6AA). After sorting
was completed, lysis buffer was added to 1 ml, and samples
were centrifuged for 10 min at 500 ×g (4°C) and further pro-
cessed as originally described (Buenrostro et al., 2013). ATAC-
seq libraries were sequenced on an Illumina HiSeq2500
(paired-end read mode, 51-bp read length), and reads were
aligned to the human genome (hg38 build) using HISAT2 (Kim
et al., 2015). Paired alignments spanning >1,000 bp were fil-
tered from the alignments, and MACS2 software was used to
call peaks. Overlapping and nonoverlapping regions/peaks
between two samples were identified using the intersect
function of BEDTools (Quinlan and Hall, 2010) or the HOMER
(Heinz et al., 2010) mergePeaks script (-d given option) re-
quiring a minimal overlap of 1 bp. Only peaks found in at least
two out of three replicates were kept for downstream analysis.
The HOMER annotatePeaks script was then used to quantify
normalized read densities for all reproducible peaks (n =
26,192) in each replicate dataset. Differentially enriched peaks
were selected based on changes in normalized average read
density (>2.0 fold) and statistical significance (P < 0.05, paired
t test), after which we removed low signal peaks (<3.0 average
log2 normalized read density in both ILC subsets). Gene-peak
associations were obtained using the HOMER annotatePeaks
script; pathway enrichment analysis was performed using
Metascape (Tripathi et al., 2015). PCA and Ward hierarchical
clustering were performed in R using RStudio (v1.1.463).
Statistical analysis
Data are represented as individual values with mean unless
specified. Sample size for each experiment and the replicate
number of experiments are included in the figure legends.
Data and software availability
The data reported in this paper have been uploaded to the Gene
Expression Omnibus with the accession numbers GSE123817 and
GSE124054.
Contact for reagent and resource sharing
Further information and requests for resources and reagents
should be directed to and will be fulfilled by corresponding
author Hergen Spits.
Online supplemental material
Fig. S1 shows further HSNE analysis of cluster B as identified by
HSNE analysis of total PB ILCs; CD200R expression on ILC
subsets and NK cells; HSNE analysis of total tonsil ILCs; ILC
distribution in PB, tonsils, and NPs; and the frequency of KLRG1+
ILCs in these tissues. Fig. S2 shows the phenotype of PB KLRG1+
ILCs, NKp46+ ILCs, ILC2s, and tonsil NKp44− and NKp44+ ILC3s
after culture on OP9-DL1 cells with IL-2 and IL-7 and relative
expression of RORC, EOMES, TBX21, GZMB, and PRF1 in different
ILC subsets isolated from PB and tonsils. Fig. S3 shows the TF
expression in different KLRG1+ and NKp46+ ILC clones and the
cytokine production from bulk and clonal differentiation cul-
tures of NKp46− ILCs. Fig. S4 shows additional genome browser
shots of ATAC-seq signals across key loci relevant for ILC de-
velopment and differentiation. Fig. S5 shows the cytokine pro-
duction profile of freshly isolated NKp44− and NKp44+ ILC3s
from tonsils.
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Figure 4. KLRG1+ ILCs and NKp46+ ILCs show multipotent 
cytokine production and TF profi le. (A) Representative 
histogram of expression of CD25 or RANKL on KLRG1+ ILCs, 
ILC2s, and NKp46+ ILCs aft er culture on OP9-DL1 cells in the 
presence of IL-2 and IL-7 with or without TSLP and IL-33 or IL-
1β and IL-23 for 7 d. (B) Quantifi cation of CD25 or RANKL 
expression on aft er culture as in A (n = 3–8). (C) Representa-
tive fl ow cytometric analysis of intracellular IL-5, IL-13, IFN-γ, 
and IL-17A in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs, aft er 7 d 
culture as in A and subsequently stimulated by PMA/iono-
mycin for 3 h. (D) Quantifi cation of cytokine production by 
ELISA in culture supernatants from cells stimulated as in A. 
Th e concentration is adjusted to 5,000 cells. (E) Quantifi ca-
tion of IFN-γ production by ELISA of ILC subsets cultured on 
OP9-DL1 cells in the presence of IL-2 and IL-7 with IL-1β and 
IL-23 or IL-1β and IL-12 for 7 d. (F) Representative fl ow cytom-
etry of the expression of CD117, NKp44, and CD94 on KLRG1+ 
ILCs, ILC2, and NKp46+ ILCs aft er culture as in E. Filled his-
tograms represent isotype control. (G) Representative fl ow 
cytometric analysis of intracellular expression of EOMES and 
T-bet in KLRG1+ ILCs, ILC2s, and NKp46+ ILCs aft er culture as 
in E. Data in A, C, F, and G are representative of at least three 
donors from more than three independent experiments. 
Cytokines used in all experiments are IL-2 (20 U/ml), IL-7, 
TSLP, IL-33, IL-1β, IL-23, and IL-12 (all 20 ng/ml). **, P < 0.001; 
***, P < 0.0001; ****, P < 0.00001 (one-way ANOVA).
2222
